229 related articles for article (PubMed ID: 36012442)
1. Full-Length Dystrophin Restoration via Targeted Exon Addition in DMD-Patient Specific iPSCs and Cardiomyocytes.
Xiao R; Zhou M; Wang P; Zeng B; Wu L; Hu Z; Liang D
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012442
[TBL] [Abstract][Full Text] [Related]
2. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs.
Zeng B; Zhou M; Liu B; Shen F; Xiao R; Su J; Hu Z; Zhang Y; Gu A; Wu L; Liu X; Liang D
Biochem Biophys Res Commun; 2021 Mar; 545():40-45. PubMed ID: 33540285
[TBL] [Abstract][Full Text] [Related]
3. Restoring Dystrophin Expression with Duchenne Muscular Dystrophy Exon 45 Skipping in Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Sato M; Shiba N; Miyazaki D; Shiba Y; Nakamura A
Methods Mol Biol; 2023; 2587():141-151. PubMed ID: 36401028
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of intracellular Ca
Sato M; Shiba N; Miyazaki D; Shiba Y; Echigoya Y; Yokota T; Takizawa H; Aoki Y; Takeda S; Nakamura A
Biochem Biophys Res Commun; 2019 Nov; 520(1):179-185. PubMed ID: 31585729
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice.
Zhang Y; Long C; Li H; McAnally JR; Baskin KK; Shelton JM; Bassel-Duby R; Olson EN
Sci Adv; 2017 Apr; 3(4):e1602814. PubMed ID: 28439558
[TBL] [Abstract][Full Text] [Related]
6. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
7. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
8. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
[TBL] [Abstract][Full Text] [Related]
9. A Novel CRISPR-Cas9 Strategy to Target DYSTROPHIN Mutations Downstream of Exon 44 in Patient-Specific DMD iPSCs.
Dhoke NR; Kim H; Azzag K; Crist SB; Kiley J; Perlingeiro RCR
Cells; 2024 Jun; 13(11):. PubMed ID: 38891104
[TBL] [Abstract][Full Text] [Related]
10. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
[TBL] [Abstract][Full Text] [Related]
11. Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations.
Dick E; Kalra S; Anderson D; George V; Ritso M; Laval SH; Barresi R; Aartsma-Rus A; Lochmüller H; Denning C
Stem Cells Dev; 2013 Oct; 22(20):2714-24. PubMed ID: 23829870
[TBL] [Abstract][Full Text] [Related]
12. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
[TBL] [Abstract][Full Text] [Related]
13. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
14. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing.
Chemello F; Chai AC; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Atmanli A; Mireault AA; Liu N; Bassel-Duby R; Olson EN
Sci Adv; 2021 Apr; 7(18):. PubMed ID: 33931459
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells.
Min YL; Li H; Rodriguez-Caycedo C; Mireault AA; Huang J; Shelton JM; McAnally JR; Amoasii L; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2019 Mar; 5(3):eaav4324. PubMed ID: 30854433
[TBL] [Abstract][Full Text] [Related]
16. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing.
Long C; Li H; Tiburcy M; Rodriguez-Caycedo C; Kyrychenko V; Zhou H; Zhang Y; Min YL; Shelton JM; Mammen PPA; Liaw NY; Zimmermann WH; Bassel-Duby R; Schneider JW; Olson EN
Sci Adv; 2018 Jan; 4(1):eaap9004. PubMed ID: 29404407
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients.
Eisen B; Ben Jehuda R; Cuttitta AJ; Mekies LN; Shemer Y; Baskin P; Reiter I; Willi L; Freimark D; Gherghiceanu M; Monserrat L; Scherr M; Hilfiker-Kleiner D; Arad M; Michele DE; Binah O
J Cell Mol Med; 2019 Mar; 23(3):2125-2135. PubMed ID: 30618214
[TBL] [Abstract][Full Text] [Related]
19. Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells.
Pioner JM; Guan X; Klaiman JM; Racca AW; Pabon L; Muskheli V; Macadangdang J; Ferrantini C; Hoopmann MR; Moritz RL; Kim DH; Tesi C; Poggesi C; Murry CE; Childers MK; Mack DL; Regnier M
Cardiovasc Res; 2020 Feb; 116(2):368-382. PubMed ID: 31049579
[TBL] [Abstract][Full Text] [Related]
20. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
